0001493152-26-022608
SEC filingMIRA Pharmaceuticals announced the peer-reviewed publication of preclinical data for SKNY-1, its investigational oral drug candidate for obesity and nicotine addiction, showing dose-dependent weight loss (~30% reduction), lipid normalization, and behavioral attenuation in zebrafish models; SKNY-1 remains unapproved and未经 human clinical validation.
This 8-K discloses the peer-reviewed publication of preclinical data for SKNY-1 in the International Journal of Molecular Sciences, representing a milestone in MIRA’s early-stage pipeline development. The findings — including ~30% weight reduction, lipid normalization, and behavioral modulation in an MC4R-deficient zebrafish model — are mechanistically detailed and internally consistent with prior reported preclinical work on CB1 pathway engagement and anxiety-like behavior attenuation. However, all results derive exclusively from non-mammalian and in vitro systems; no human safety, pharmacokinetic, or efficacy data are presented, and the compound has not entered clinical trials. While the publication strengthens scientific credibility and may support future regulatory interactions or partnering discussions, it does not alter the developmental risk profile: SKNY-1 remains preclinical, unapproved, and without established human tolerability or activity. Investors should recognize this as a scientific update rather than a clinical or commercial inflection point.